News

  • 20 February 2019

    Intercept reports fibrosis improvement in NASH trial

    Intercept Pharmaceuticals has reported positive top-line results from the pivotal Phase III REGENERATE clinical trial of obeticholic acid (OCA) in patients with liver fibrosis caused due to non-alcoholic steatohepatitis (NASH).

Go Top